Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos (e.g., Chromones, Etc.) Patents (Class 514/456)
-
Patent number: 11000502Abstract: Copper based antibacterial agents are described based on amphiphilic copper complexes formed between copper and hydroxypyrones, such as maltol. In further aspects, the present invention relates to PEG based-ointments showing that they are particularly effective for topical delivery of amphiphilic complexes of copper. In particular, PEG ointments were shown to limit bacterial growth, even when in the absence of copper agent. However, this bacteriostatic effect is shown herein to become a true biocidal effect when copper hydroxypyrones are added to the PEG.Type: GrantFiled: February 6, 2018Date of Patent: May 11, 2021Assignee: United Kingdom Research and InnovationInventors: Jonathan Joseph Powell, Nuno Jorge Rodrigues Faria, Carlos Andre Passos Bastos
-
Patent number: 10993958Abstract: Compositions comprising aldehyde functional monoterpenoids in combination with 3,3?,4?,7-tetrahydroxyflavone, zinc, and a 5-beta-D-Ribofuranosylpicolineamide adenine-dinucleotide molecule are provided for treating viral infections, e.g., coronavirus infections such as COVID-19.Type: GrantFiled: May 22, 2020Date of Patent: May 4, 2021Inventor: William B. Coe
-
Patent number: 10980772Abstract: Disclosed herein are “ketannabis” (or “ketonnabis”) compositions including a combination of: (1) tetrahydrocannabinol (THC); (2) a ketone body component such as beta-hydroxybutyrate (BHB) and/or acetoacetate; and (3) a dietetically or pharmaceutically acceptable carrier. Also disclosed herein are methods of using such ketannabis compositions for producing desired physiological effects. The ketannabis compositions beneficially enhance the euphoric effects of THC without aggravating common side effects or even acting to reduce common side effects such as anxiety, disruption of short-term memory, appetite increases, heart rate increases, and blood pressure changes.Type: GrantFiled: February 11, 2019Date of Patent: April 20, 2021Assignee: AXCESS GLOBAL SCIENCES, LLCInventor: Gary Millet
-
Patent number: 10959979Abstract: Compounds capable of, or usable in, killing cancer cells, and/or modulating a biological activity of a chemokine, and/or inhibiting a kinase, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or treating disease and disorders such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are listed in Tables 2, 4 and 5, and/or are represented by Formulae I, IV, V and VI, as defined in the specification. Methods utilizing these compounds are also provided.Type: GrantFiled: May 7, 2020Date of Patent: March 30, 2021Assignee: Biokine Therapeutics Ltd.Inventors: Amnon Peled, Michal Abraham Karni, Orly Eizenberg
-
Patent number: 10952965Abstract: The present disclosure is directed to surface-modified particles and to methods of making and using the same.Type: GrantFiled: May 15, 2009Date of Patent: March 23, 2021Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Barrett Rabinow, Shawn F. Bairstow, Mahesh V. Chaubal, Sarah Lee, Jane Werling
-
Patent number: 10925918Abstract: A composition for food and a fat absorption inhibitor, each including a seaweed polyphenol and a tea extract.Type: GrantFiled: January 21, 2015Date of Patent: February 23, 2021Assignee: FUJIFILM CornorationInventors: Yuriko Oda, Fumitaka Ueda
-
Patent number: 10888574Abstract: The present disclosure relates to a method for suppressing obesity, which includes administering to a subject a compound represented by the following formula wherein n is an integer of 1 to 5; when n is 1, R1 is —OH or —O-glycosyl; when n is an integer of 2 to 5, one R1 is —OH and the other R1(s) is/are —O-glycosyl; and R2 is -glycosyl.Type: GrantFiled: September 28, 2018Date of Patent: January 12, 2021Assignee: KINJIRUSHI CO.. LTD.Inventors: Isao Okunishi, Tomoe Kato
-
Patent number: 10874634Abstract: Compounds described herein are inhibitors of retinoic acid inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated catabolism, and are used for treating diseases that are responsive to retinoids.Type: GrantFiled: December 13, 2017Date of Patent: December 29, 2020Assignee: Queen's University at KingstonInventors: Donald Andrew Cameron, Martin Petkovich, Toni Kristian Rantanen, Victor Snieckus, Johnathan Board, Suneel Singh, Ashishkumar Jayantilal Maheta
-
Patent number: 10849862Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.Type: GrantFiled: December 24, 2015Date of Patent: December 1, 2020Assignee: THERAVALUES CORPORATIONInventors: Yutaka Kawakami, Tomonori Yaguchi, Taeko Hayakawa, Atsushi Imaizumi
-
Patent number: 10844073Abstract: Provided herein are palladium-mediated coupling reactions useful in the preparation of ketone-containing organic molecules. The provided methods can be used for the preparation of natural products and pharmaceutical agents, including Eribulin, halichondrins, and analogs thereof. The present invention also provides novel halichondrin analogs which can be prepared via the palladium-mediated coupling reactions. The novel halichondrin analogs can be used in the prevention and/or treatment of diseases or conditions (e.g., proliferative diseases such as cancer).Type: GrantFiled: July 1, 2019Date of Patent: November 24, 2020Assignee: President and Fellows of Harvard CollegeInventors: Jung Hwa Lee, Yoshito Kishi, Ayumi Osawa, Zhanjie Li
-
Patent number: 10786531Abstract: The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions.Type: GrantFiled: June 24, 2019Date of Patent: September 29, 2020Assignee: BMG PHARMA SPAInventors: William A. Goolsbee, Jeffrey L. Lillard
-
Patent number: 10766872Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:Type: GrantFiled: May 31, 2017Date of Patent: September 8, 2020Assignee: The Board Institute, Inc.Inventors: Deborah Hung, Sarah Stanley, Tomohiko Kawate, Noriakie Iwase, Motohisa Shimizu
-
Patent number: 10765660Abstract: A pharmaceutical composition for the prevention and treatment of cancer with specific flavanoid-based compounds selected from among the groups of Flavone, Flavanone and Flavanol, a method for the prevention and treatment of cancer and inflammation using the specific flavonoid-based pharmaceutical compositions, a method for isolating the flavonoid-based pharmaceutical compositions from raw plant material, and a method for synthesizing said specific flavonoid-based pharmaceutical compositions.Type: GrantFiled: June 27, 2017Date of Patent: September 8, 2020Inventors: Henry Lowe, Ngeh J. Toyang, Joseph Bryant
-
Patent number: 10744114Abstract: A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.Type: GrantFiled: April 9, 2019Date of Patent: August 18, 2020Assignee: OSTEONEUROGEN INC.Inventors: Byung Soo Youn, Han Soo Kim, Ho Sup Yoon
-
Patent number: 10729674Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.Type: GrantFiled: July 3, 2018Date of Patent: August 4, 2020Assignee: Humanetics CorporationInventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
-
Patent number: 10703699Abstract: In one embodiment, the present application discloses compositions and methods of solubilizing pterostilbene or resveratrol, or mixture thereof in aqueous media.Type: GrantFiled: January 10, 2018Date of Patent: July 7, 2020Assignee: Ironstone Separations, Inc.Inventors: James D. McChesney, Igor Nikoulin, Douglas L. Rodenburg
-
Patent number: 10688116Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.Type: GrantFiled: March 30, 2015Date of Patent: June 23, 2020Inventors: Dania Birte Reiche, Nicole Mohren, Laura Johnston, Bruce Somerville, Rebecca K. Voth
-
Patent number: 10668157Abstract: The purpose of the present invention is to provide a polymer gel that can increase drug content ratio and reduce undesirable influence on gel strength and shape stability after the drug release, compared with the conventional techniques. The purpose can be achieved by an anionic drug-containing medical device comprising: (1) an anionic drug; and (2) a copolymer which contains, as constituents, a cationic monomer comprising a condensation product of an alkyl quaternary ammonium compound having a substituted or unsubstituted aralkyl group and (meth)acrylic acid or a salt of the condensation product and a monomer capable of copolymerizing with the condensation product or the salt of the condensation product.Type: GrantFiled: April 16, 2015Date of Patent: June 2, 2020Assignees: SEED CO., LTD., SENJU PHARMACEUTICAL CO., LTD.Inventors: Haruka Obata, Kiyoshi Shoji, Yoshiko Yamazaki, Toru Matsunaga, Takao Sato, Wakiko Asayama, Shinichi Yasueda
-
Patent number: 10668088Abstract: This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid, vitamin E and at least one carotenoid) to make a pharmaceutical, nutraceutical or food supplement which can ameliorate various problems observed in humans connected with polycystic ovarian 5 syndrome and cardiovascular diseases. Pharmaceuticals, nutraceuticals and food supplements containing the 25-OH D3 and antioxidants/anti-inflammatories and premixes are also provided.Type: GrantFiled: January 15, 2016Date of Patent: June 2, 2020Assignee: DSM IP ASSETS B.V.Inventors: Shuen Ei Chen, Thau Kiong Chung, Daniel Raederstorff, Wolfgang Schalch
-
Prodrug of green tea epigallocatechin-3-gallate (pro-EGCG) for use in the treatment of endometriosis
Patent number: 10646467Abstract: Method of treating endometriosis and related indications, comprising the administration of Pro-EGCG, a synthetic and derivative product of epigallocatechin-3-gallate [(?)-EGCG]. Use of PRO-EGCG in the manufacture of a medicament for treating endometriosis and related indications. Pro-EGCG for use in the treatment of endometriosis and related indications.Type: GrantFiled: January 28, 2019Date of Patent: May 12, 2020Inventors: Tak-Hang Chan, Chi-Chiu Wang -
Patent number: 10646465Abstract: Compounds capable of, or usable in, killing cancer cells, and/or modulating a biological activity of a chemokine, and/or inhibiting a kinase, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or treating disease and disorders such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are listed in Tables 2, 4 and 5, and/or are represented by Formulae I, IV, V and VI, as defined in the specification. Methods utilizing these compounds are also provided.Type: GrantFiled: December 15, 2016Date of Patent: May 12, 2020Assignee: Biokine Therapeutics Ltd.Inventors: Amnon Peled, Michal Abraham, Orly Eizenberg
-
Patent number: 10632098Abstract: The present invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected from the group of Apigenin, Cannflavin A, Cannflavin B, Cannflavin C, Chiysoeriol, Cosmosiin and Flavocannabiside or their synthases, for the prevention and treatment of certain ocular diseases and related disorders.Type: GrantFiled: February 27, 2019Date of Patent: April 28, 2020Inventors: Henry I C Lowe, Ngeh J. Toyang
-
Patent number: 10626109Abstract: The present invention relates to fungicidal N-hetarylcarbonyl-2-(benzocycloalken-1-yl)piperidines or pyrrolidines of formula (I), and their thiocarbonyl derivatives, wherein A represents a carbo-linked, unsaturated or partially saturated, 5-membered heterocyclyl group that can be substituted by up to four groups R that can be the same or different; T represents 0 or S; n represents 1 or 2; m represents 1, 2 or 3; p represents 1, 2, 3 or 4, L1 and L2 independently represent CZ4Z5, NZ6, 0, S, S(O) or S(0)2; and R and Z1-Z6 are as defined in the claims; their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions.Type: GrantFiled: October 7, 2014Date of Patent: April 21, 2020Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFTInventors: Philippe Desbordes, Philippe Rinolfi, Tomoki Tsuchiya
-
Patent number: 10603349Abstract: The present invention relates to a method for preparing a granulate composition of rhizomes from Alpinia galanga or Alpinia conchigera having a high and stable content of 1?S-1?-acetoxychavicol acetate and low microbiological count, which is suitable for preparing orally ingestible dosage forms such as tablets or capsules.Type: GrantFiled: October 1, 2015Date of Patent: March 31, 2020Assignee: NERTHUS APSInventors: Henrik Byrial Jakobsen, Ina Giversen
-
Patent number: 10596185Abstract: This invention relates to a flavonoid composition that includes eriocitrin. The flavonoid may be included in a complex with other bioflavonoids. The composition may also include neoeriocitrin. This invention also relates to methods of using the composition, including for reducing IL-6 or MCP-1 levels, treating inflammation, and treating symptoms of metabolic syndrome.Type: GrantFiled: March 31, 2015Date of Patent: March 24, 2020Assignees: INGREDIENTS BY NATURE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTUREInventors: Robert M. Brewster, John A. Manthey
-
Patent number: 10548938Abstract: The object is to provide a method of manufacturing a fraction containing nobiletin and tangeretin at high concentrations, which is excellent in terms of safety, economic efficiency, and the potential for industrialization. The method includes (1-1) a step of treating citrus fruit with hot water to obtain a hot water-treated product; (1-2) a step of drying the hot water-treated product to obtain a dried product; (1-3) a step of treating the dried product with a solvent capable of dissolving nobiletin and tangeretin to obtain a nobiletin and tangeretin solution; (3) a step of concentrating and/or drying the nobiletin and tangeretin solution to obtain a nobiletin and tangeretin concentrate; and (4) a step of treating the nobiletin and tangeretin concentrate with a dilute alkali to obtain a composition containing nobiletin and tangeretin as an insoluble component, and by a composition containing nobiletin and tangeretin at high concentrations manufactured by the method.Type: GrantFiled: August 9, 2013Date of Patent: February 4, 2020Assignees: UNIVERSITY OF THE RYUNKYUS, OKINAWA RESEARCH CENTER CO., LTD.Inventors: Toshiaki Teruya, Yuto Teruya, Saki Sugiyama, Je-Tae Woo
-
Patent number: 10543277Abstract: A medicinal composition useful for the treatment of head and neck cancer premalignant lesions. The composition includes a curcuminoid mixture and an essential oil of turmeric. The curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin. The essential oil of turmeric includes about 45% ar-turmerone. The weight ratio of curcuminoid mixture to essential oil of turmeric ranges from about 1:3 to about 99:1. Methods of preparation of the composition is provide. Methods of treatment of head and neck cancer premalignant lesions by oral administration is provided.Type: GrantFiled: April 29, 2015Date of Patent: January 28, 2020Assignee: ARJUNA NATURAL PRIVATE LIMITEDInventors: Benny Antony, Moni Abraham Kuriakose
-
Patent number: 10544157Abstract: The present invention provides a process for the preparation of darunavir or solvates or a pharmaceutically acceptable salt thereof substantially free of bisfuranyl impurities, particularly darunavir propionate solvate. The present invention also provides a process for preparation amorphous darunavir using the darunavir propionate solvate.Type: GrantFiled: January 10, 2019Date of Patent: January 28, 2020Assignee: LAURUS LABS LIMITEDInventors: Kameswar R. Chivukula, Venkata R. Murthy, Venkata S. Indukuri, Seeta R. Gorantla
-
Patent number: 10537547Abstract: Disclosed are methods of favouring epithelial wound healing in a subject. Wounds suitable for this method include wounds located on the skin or in a cornea The methods comprise contacting a wound with an activator of an AKT pathway and/or an inhibitor of the MAPK pathway such as CREB inhibitors. Preferred compounds include SC-79, C646, curcumin, platelet-derived growth factor, 4?chloro-3-hydroxy-2-naphthanilide and fumonisin B. A model for wound healing is also disclosed. The model can be used to identify test compounds that are AKT activators or inhibitors of MAPK pathway, which are suitable to favoring epithelial wound healing.Type: GrantFiled: November 4, 2016Date of Patent: January 21, 2020Inventors: Sylvain Guerin, Lucie Germain, Karine Zaniolo, Camille Couture, Pascale Desjardins
-
Patent number: 10500145Abstract: A temporary tattooing ink is produced from concentrated genipin. In one embodiment, the concentrated genipin forms part of a solution. In another embodiment, the genipin is provided in a gel form which also includes a solvent and a thickening agent. Finally, an applicator is described into which genipin may be embedded for applying to a user's skin.Type: GrantFiled: June 10, 2016Date of Patent: December 10, 2019Assignee: inkbox ink inc.Inventors: Tyler James Handley, Braden Handley, Christopher Blain Caputo, Adam Manuel Zrehen
-
Patent number: 10391113Abstract: Disclosed are a compound pharmaceutical composition containing Cichorium glandulosum Boiss et Hout as a lipid-lowering active ingredient and the use of the composition for preparing a drug for treating or preventing lipid metabolism disorders, wherein the composition comprises a pharmaceutically active ingredient and a pharmaceutically acceptable carrier, wherein the pharmaceutically active ingredient consists of quercetin-3-O-?-D-glucuronoside, isoquercitrin and quercetin at a molar ratio of 1.1-2.4:1.3-3.3:1.2-3.1.Type: GrantFiled: March 6, 2015Date of Patent: August 27, 2019Assignee: NANJING RUIYING RUNZE BIOPHARMAEUTICAL TECHNOLOGY CO., INC.Inventors: Jing Shang, Lin Ding, Guohong Qin, Tao Wang, Jun Liu, Yu Li, Ting He
-
Patent number: 10392361Abstract: The present invention relates to a novel process for the synthesis of the intermediate compounds constituted by chromanyl haloketones of formula III and 6-fluoro-2-(oxiran-2-yl)chromans of formula I. The intermediates thus obtained can be used for the synthesis of Nebivolol.Type: GrantFiled: January 23, 2017Date of Patent: August 27, 2019Assignee: Menarini International Operations Luxembourg S.A.Inventors: Sandra Bartoli, Serena Mannucci, Alessio Griselli, Alessio Stefanini
-
Patent number: 10392400Abstract: Provided herein are palladium-mediated coupling reactions useful in the preparation of ketone-containing organic molecules. The provided methods can be used for the preparation of natural products and pharmaceutical agents, including Eribulin, halichondrins, and analogs thereof. The present invention also provides novel halichondrin analogs which can be prepared via the palladium-mediated coupling reactions. The novel halichondrin analogs can be used in the prevention and/or treatment of diseases or conditions (e.g., proliferative diseases such as cancer).Type: GrantFiled: November 10, 2017Date of Patent: August 27, 2019Assignee: President and Fellows of Harvard CollegeInventors: Jung Hwa Lee, Yoshito Kishi, Ayumi Osawa, Zhanjie Li
-
Patent number: 10370364Abstract: A compound represented by the following Formula 1 or a pharmaceutically acceptable salt thereof: wherein R1 is a substituted or unsubstituted C1-5 linear or branched alkyl, a C5-6 cycloalkyl, a C5-6 cycloalkyl containing at least one heteroatom selected from among O and N, a substituted or unsubstituted C6-12 aryl, or a C5-6 heteroaryl containing at least one heteroatom selected from among O and N; R2 is hydrogen, ethyl, acetyl, acetoxy, carboxy, benzoyloxy or 3,4,5-trihydroxybenzoyloxy; and R3 to R5 are each independently hydrogen, hydroxyl, methyl, methoxy, acetoxy, carboxy or benzoyloxy.Type: GrantFiled: July 17, 2018Date of Patent: August 6, 2019Assignee: OSTEONEUROGEN INC.Inventors: Byung Soo Youn, Jun Hwan Kim, Han Soo Kim, Ho Sup Yoon, Ik Hwan Kim
-
Patent number: 10369132Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.Type: GrantFiled: April 24, 2018Date of Patent: August 6, 2019Assignee: MEI PHARMA, INC.Inventor: Ofir Moreno
-
Patent number: 10370350Abstract: The present disclosure relates to salts of the compound (I), polymorphic forms thereof, methods for preparation and use thereof, and pharmaceutical compositions thereof.Type: GrantFiled: September 5, 2014Date of Patent: August 6, 2019Assignee: Research Development FoundationInventors: Michael O'Neill, Barbara Kidon, Thomas Adkins, Hongqiao Wu, Emmanuel T. Akporiaye
-
Patent number: 10342777Abstract: A caffeoylquinic acid-rich extract obtained from Erigeron multiradiatus and a method for producing the same. A caffeoylquinic acid-rich extract includes at least 15% by weight of a mixture of certain caffeoylquinic acids. The extract with the mixture of caffeoylquinic acids is highly efficacious in treating and preventing myocardial ischemia or myocardial ischemia reperfusion injuries. A method for treating or preventing a disease caused by myocardial ischemia or myocardial ischemia reperfusion includes administering a therapeutically effective amount of the caffeoylquinic acid-rich extract to a subject. Pharmaceutical compositions including the caffeoylquinic acid-rich extract are also disclosed.Type: GrantFiled: October 1, 2015Date of Patent: July 9, 2019Assignee: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Pei Luo, Zhifeng Zhang, Hao Zhang
-
Patent number: 10322130Abstract: The present invention provides PI3K protein kinase modulators of formula wherein R, Cy1, R1, R2, L1 and Cy2 are as defined herein. The present invention also relates to methods of preparing compounds of formula (I) to pharmaceutical compositions containing them and to methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.Type: GrantFiled: August 15, 2017Date of Patent: June 18, 2019Assignee: RHIZEN PHARMACEUTICALS SAInventors: Dhanapalan Nagarathnam, Swaroop K. Vakkalanka, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Prashant K. Bhavar
-
Patent number: 10316053Abstract: The present disclosure provides a compound of the following formula, racemates, enantiomers, prodrugs and salts thereof: Also provided is the use of these compounds for the treatment of ischemia and reperfusion injuries. Further applications include the treatment of diseases caused by cell apoptosis and/or cell necrosis.Type: GrantFiled: October 11, 2013Date of Patent: June 11, 2019Assignee: ARMARON BIO PTY LTDInventor: Grant McLachlan
-
Patent number: 10314810Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.Type: GrantFiled: July 27, 2011Date of Patent: June 11, 2019Assignees: Trustees of Boston University, Northeastern University, Boston Medical Center CorporationInventors: David H. Sherr, Michael Pollastri, Jennifer Schlezinger, Sarah Haigh Molina, Scott Schaus, Joshua Robert Giguere
-
Patent number: 10294239Abstract: The present invention relates to processes for the preparation of an ertugliflozin-L-pyroglutamic acid (1:1) and co-crystal ertugliflozin-L-proline (1:1) co-crystal. The present invention further relates to an ertugliflozin-L-proline (1:2) co-crystal, processes for its preparation, and its use for the treatment of type 2 diabetes mellitus.Type: GrantFiled: May 24, 2016Date of Patent: May 21, 2019Assignee: Sun Pharmaceutical Industries LimitedInventors: Ramkinkar Santra, Bala Krishna Reddy Bhogala, Chandra Has Khanduri
-
Patent number: 10238625Abstract: Methods for the treatment of systemic mast cell related disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.Type: GrantFiled: August 5, 2016Date of Patent: March 26, 2019Assignee: RESPIVANT SCIENCES GMBHInventors: William Gerhart, Pravin Soni, Ahmet Tutuncu
-
Patent number: 10206901Abstract: A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol and, optionally, terpenes such as linalool.Type: GrantFiled: September 20, 2017Date of Patent: February 19, 2019Assignee: JC Pharma, Inc.Inventors: Jason Allen Cranford, Donald Channing Cooper
-
Patent number: 10188747Abstract: The technology described herein is directed to agonists of, e.g. Esr2, Dlx5, and/or Egr3, for the inhibition of cancer cells (e.g. squamous carcinoma cancer cells) and the treatment of cancer.Type: GrantFiled: February 12, 2015Date of Patent: January 29, 2019Assignee: The General Hospital CorporationInventors: Gian Paolo Dotto, Yang Sui Brooks
-
Patent number: 10105346Abstract: Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.Type: GrantFiled: March 10, 2017Date of Patent: October 23, 2018Assignee: MEI PHARMA, INC.Inventors: George Jeoffreys, Alison Johnson, Andrew Heaton, Ofir Moreno
-
Patent number: 10105344Abstract: The present invention is directed to methods for reducing blood lactate concentration during exercise, physical activity or athletic performance.Type: GrantFiled: June 22, 2017Date of Patent: October 23, 2018Assignee: Stokely-Van Camp, Inc.Inventors: Jeffrey J. Zachwieja, Mark Arthur Pirner, JohnEric William Smith
-
Patent number: 10098915Abstract: An equol-producing lactic acid bacteria-containing composition comprises, as an essential component thereof, a lactic acid bacterial strain belonging to the genus Lactococcus having an ability to utilize at least one daidzein compound selected from the group consisting of daidzein glycosides, daidzein, and dihydrodaidzein to produce equol. Such a composition is effective for the prevention and alleviation of malaise inclusive of climacteric disturbance in middle-aged and elderly women for which no effective prophylactic method or alleviating means has heretofore been available.Type: GrantFiled: September 24, 2013Date of Patent: October 16, 2018Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Shigeto Uchiyama, Tomomi Ueno, Toshimi Suzuki
-
Patent number: 10072055Abstract: Polypeptides having homology to regions of the N-terminal 50 residues of human Annexin 1 are provided for medical use as anti-inflammatory agents. Some of the polypeptides have homology to the N-terminal 48 residues of human Annexin 1, especially to residues 2-48 and 11-48 thereof. In some embodiments, properties of these compounds are improved by at least one modification at residues corresponding to residues 11, 22, 25 and/or 36 of human Annexin 1, and/or by C-terminal amidation of the polypeptide. Analogs of amino acids 2-26 of human Annexin 1, especially acetylated at the N-terminus and/or amidated at the C-terminus and having modifications at 11 and/or 22 are also disclosed for medical use as anti-inflammatory agents.Type: GrantFiled: July 20, 2015Date of Patent: September 11, 2018Assignee: Resother Pharma APSInventors: Angelo P. Consalvo, Nozer M. Mehta, Mauro Perretti, Jesmond Dalli
-
Patent number: 10045961Abstract: Provided herein are methods of treating a subject having hepatitis B viral (HBV) infection. More specifically, disclosed herein are methods of stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular agonists of STING to suppress HBV replication in hepatocytes. The methods are especially suitable for use in the treatment of chronic HBV infections. Also disclosed herein are methods of identifying compounds useful in the treatment of HBV infection.Type: GrantFiled: April 10, 2017Date of Patent: August 14, 2018Assignee: Drexel UniversityInventors: Jinhong Chang, Fang Guo, Timothy M. Block, Ju-Tao Guo
-
Patent number: 10039739Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.Type: GrantFiled: July 6, 2017Date of Patent: August 7, 2018Assignee: Humanetics CorporationInventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk